Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
PMID: 41898733
The analysis found low doses were as effective as full doses for preventing recurrent VTEs, but low-dose DOAC therapy reduced the risks of major and clinically relevant non-major bleeding events compared with full-dose therapy, with no significant differences between apixaban and rivaroxaban
Important Disclaimer
Your research is too important to cut corners
Research has shown that tissue repair needs a push of peptide availability at the start to drive cell migration and new blood vessel growth at the injury site
US$ 21.36
US$ 26.98
US$ 23.87
US$ 26.15
US$ 24.70
